

# Francisco MartÃ-nez-Ricarte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9367899/publications.pdf>

Version: 2024-02-01

43  
papers

2,820  
citations

430442

18  
h-index

329751

37  
g-index

49  
all docs

49  
docs citations

49  
times ranked

5427  
citing authors

#	ARTICLE	IF	CITATIONS
1	Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis. <i>Cancer Research</i> , 2022, 82, 2552-2564.	0.4	6
2	Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. <i>Haematologica</i> , 2021, 106, 513-521.	1.7	75
3	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. <i>Nature Communications</i> , 2021, 12, 1503.	5.8	45
4	ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. <i>Cancers</i> , 2021, 13, 1989.	1.7	26
5	Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. <i>Journal of Neuro-Oncology</i> , 2020, 149, 13-25.	1.4	11
6	Isolated cerebral mucormycosis associated with intravenous drug use. <i>Journal De Mycologie Medicale</i> , 2020, 30, 101046.	0.7	2
7	Tumor-associated status epilepticus: A prospective cohort in a tertiary hospital. <i>Epilepsy and Behavior</i> , 2020, 111, 107291.	0.9	5
8	Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. <i>Nature Communications</i> , 2020, 11, 5376.	5.8	67
9	Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies. <i>Current Opinion in Neurology</i> , 2020, 33, 736-741.	1.8	4
10	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , 2019, 10, 2416.	5.8	150
11	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268.	2.5	45
12	Prognosis in patients with brain tumor-associated status epilepticus. <i>Epilepsy and Behavior</i> , 2019, 101, 106775.	0.9	0
13	REVERSAL OF IMMUNE TOLERANCE AND INCREASED SURVIVAL AFTER XPO1 AND BTK INHIBITION IN MOUSE MODELS OF PRIMARY CNS LYMPHOMA (PCNSL). <i>Hematological Oncology</i> , 2019, 37, 321-322.	0.8	0
14	ANALYSIS OF CIRCULATING TUMOR DNA (ctDNA) IN CEREBROSPINAL FLUID DETECTS THE PRESENCE OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2019, 37, 188-190.	0.8	0
15	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	13.7	637
16	A rare case of an intramedullary metastasis of a myxopapillary ependymoma. , 2019, 10, 83.		7
17	Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. , 2019, , .		0
18	Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. <i>Clinical Cancer Research</i> , 2018, 24, 2812-2819.	3.2	128

#	ARTICLE	IF	CITATIONS
19	Aneurisma gigante no traumático de la arteria menáigea media. A propósito de un caso y revisión de la literatura. Neurocirugia, 2018, 29, 250-254.	0.2	0
20	Alteraciones neuropsicológicas y hallazgos neurorradiológicos en pacientes con conmoción cerebral postraumática. Resultados de un estudio piloto. Neurología, 2018, 33, 427-437.	0.3	1
21	Outcome of cancer-related seizures in patients treated with lacosamide. Acta Neurologica Scandinavica, 2018, 137, 67-75.	1.0	17
22	Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors. Annals of Oncology, 2018, 29, viii123.	0.6	0
23	ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi5-vi5.	0.6	0
24	Fuzzy Approach to Grade Gliomas using Susceptibility-Weighted Images. A Preliminary Study. , 2018, , .		0
25	OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial. Neuro-Oncology, 2018, 20, iii219-iii219.	0.6	0
26	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145.	2.5	41
27	Epileptic features and survival in glioblastomas presenting with seizures. Epilepsy Research, 2017, 130, 1-6.	0.8	49
28	Target location after deep cerebral biopsies using low-volume air injection in 75 patients. Results and technical note. Acta Neurochirurgica, 2017, 159, 1939-1946.	0.9	4
29	Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report. Journal of Neurosurgery: Pediatrics, 2016, 18, 53-57.	0.8	9
30	pelF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas. Cancer Medicine, 2016, 5, 2501-2512.	1.3	29
31	Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. , 2016, , .		1
32	Prognostic implications of epilepsy in glioblastomas. Clinical Neurology and Neurosurgery, 2015, 139, 166-171.	0.6	42
33	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications, 2015, 6, 8839.	5.8	605
34	Role of [ 11 C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. Clinical Neurology and Neurosurgery, 2015, 139, 328-333.	0.6	14
35	Abstract 930: Analysis of cell-free tumor DNA in cerebrospinal fluid to characterize and monitor the genetic alterations of brain tumors. Cancer Research, 2015, 75, 930-930.	0.4	2
36	Nitric Oxide Synthase Inhibition with the Antipterin VAS203 Improves Outcome in Moderate and Severe Traumatic Brain Injury: A Placebo-Controlled Randomized Phase IIa Trial (NOSTRA). Journal of Neurotrauma, 2014, 31, 1599-1606.	1.7	50

#	ARTICLE	IF	CITATIONS
37	Head circumference: The forgotten tool for hydrocephalus management. A reference interval study in the Spanish population. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 2382-2387.	0.6	4
38	Pupilometría por infrarrojos. Descripción y fundamentos de la técnica y su aplicación en la monitorización no invasiva del paciente neurocráneo. <i>Neurología</i> , 2013, 28, 41-51.	0.3	28
39	Decompressive craniectomy in traumatic brain injury after the DECRA trial. Where do we stand?. <i>Current Opinion in Critical Care</i> , 2013, 19, 101-106.	1.6	53
40	Idiopathic Normal Pressure Hydrocephalus: Results of a Prospective Cohort of 236 Shunted Patients. <i>Acta Neurochirurgica Supplementum</i> , 2012, 114, 247-253.	0.5	42
41	TGF- $\beta$ 2 Receptor Inhibitors Target the CD44 <sup>high</sup> /Id1 <sup>high</sup> Glioma-Initiating Cell Population in Human Glioblastoma. <i>Cancer Cell</i> , 2010, 18, 655-668.	7.7	534
42	Intracranial pressure monitoring with the Neurodur-P epidural sensor: a prospective study in patients with adult hydrocephalus or idiopathic intracranial hypertension. <i>Journal of Neurosurgery</i> , 2008, 108, 934-942.	0.9	15
43	INTRA-ABDOMINAL PRESSURE. <i>Neurosurgery</i> , 2008, 62, 143-150.	0.6	51